Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pneumococcal conjugate 26 valent vaccine - Beijing Zhifei Lvzhu Biopharmaceutical

Drug Profile

Pneumococcal conjugate 26 valent vaccine - Beijing Zhifei Lvzhu Biopharmaceutical

Alternative Names: 26-valent Pneumococcal Conjugate Vaccine -Beijing Zhifei Lvzhu Biopharmaceutical; PCV-26

Latest Information Update: 19 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Zhifei Lvzhu Biopharmaceutical
  • Class Conjugate vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pneumococcal infections

Most Recent Events

  • 18 May 2025 Beijing Zhifei Lvzhu Biopharmaceutical plans a phase I trial for Pneumococcal infections (Prevention) in the Australia (IM, Injection)in May 2025 (NCT06970756)
  • 27 Aug 2024 Phase-I/II clinical trials in Pneumococcal infections (Prevention, In adolescents, In adults, In children, In infants) in China (IM), (NCT06703203),
  • 01 Apr 2024 Beijing Zhifei Lvzhu Biopharmaceutical files an clinical trial application for Pneumococcal infections (Prevention) prior to April 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top